Fortrea Posts A Third-Quarter Profit And Lifts Forecast Midpoints, But Cuts Backlog By $558 Million

The clinical research firm's revenue slipped to $691.5 million while adjusted profit more than doubled, and it narrowed its 2026 ranges.

Share
Fortrea Posts A Third-Quarter Profit And Lifts Forecast Midpoints, But Cuts Backlog By $558 Million

Fortrea, the contract research organization that runs clinical trials for drugmakers, swung to a $0.6 million third-quarter net profit and raised the midpoints of its 2026 forecast, the company said Thursday. In the same quarter it cut its contract backlog by $558 million after a contract-by-contract review.

Sales dip, adjusted profit doubles

Revenue for the quarter ended September 30 was $691.5 million, down from $701.3 million a year earlier. Net income under standard accounting was $0.6 million, or $0.01 per diluted share, against a loss of $15.9 million in the third quarter of 2025.

Adjusted net income rose to $27.9 million, or $0.28 per diluted share, from $11.7 million. Adjusted EBITDA, the company's operating-profit measure that excludes items such as interest, taxes and amortization, reached $58.0 million versus $50.7 million. Cash from operations was $60.8 million and free cash flow was $52.5 million.

For the first nine months, Fortrea posted a net loss of $36.2 million. A year earlier the loss was $953.7 million, which included a non-cash goodwill impairment charge of $797.9 million.

A $558 million backlog trim

Backlog is the pipeline of signed but unfinished work. Fortrea said its review reduced it by $558 million to reflect estimated scope and study delivery requirements, including inactive trials. Adjusted backlog stood at $7,316 million at September 30.

The company said the change has no effect on historical results, current 2026 guidance or near-term revenue estimates. The book-to-bill ratio, which compares new orders with revenue, was not affected and was 1.12x for the quarter.

Narrower 2026 ranges, higher midpoints

Fortrea now expects 2026 revenue of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million. It narrowed both ranges and raised both midpoints.

CEO Anshul Thakral said the company's execution gives it "confidence to raise the midpoints of full-year guidance while narrowing ranges."

Fortrea manages phase I through IV clinical trials for drug, biotech and device makers, and 56% of its 2025 revenue came from leading pharmaceutical customers. Its earnings call was set for 8:00 a.m. ET Thursday.

Year to date, Fortrea has reported adjusted EBITDA of $163.7 million, up from $135.9 million a year earlier.

Sources